Literature DB >> 16493396

Antifilarial compounds in the treatment and control of lymphatic filariasis.

J W Mak1.   

Abstract

Diethylcarbamazine citrate (DEC) has been used for treatment and control of lymphatic filariasis since the 1950s. Although this remarkable drug is still useful and modified strategies in its usage have been developed, a number of newer antifilarial compounds are now available. Numerous field trials evaluating their efficacy in the control of lymphatic filariasis have been conducted. In particular, ivermectin (IVM), albendazole (ALB), and DEC have been tested singly and in combinations and the results of such field studies should be evaluated. While most of the studies were based on efficacy in the clearance of microfilaraemia, a few clinical trials evaluated the adulticidal activity of these compounds. Some antibiotics are effective in killing Wolbachia bacteria symbionts of filarial worms, but their role in the chemotherapy of lymphatic filariasis is still undefined. This review of randomised controlled field studies and randomised controlled clinical trials with these compounds will summarise the findings and give recommendations on their appropriate use for the control and treatment of lymphatic filariasis.

Entities:  

Year:  2004        PMID: 16493396

Source DB:  PubMed          Journal:  Trop Biomed        ISSN: 0127-5720            Impact factor:   0.623


  3 in total

1.  Effects of albendazole on Litomosoides chagasfilhoi (Nematoda: Filarioidea) females in vivo.

Authors:  Melissa Q Cárdenas; Aleksandra Oliveira-Menezes; Reinalda M Lanfredi
Journal:  Parasitol Res       Date:  2010-06-29       Impact factor: 2.289

2.  Respiratory morbidity due to ammonia exposure among the employees of a urea manufacturing industry located in western part of India.

Authors:  Naman Zala; Abhay Kavishvar
Journal:  Indian J Occup Environ Med       Date:  2012-09

3.  Evaluation of mass drug administration in the program to control imported lymphatic filariasis in Thailand.

Authors:  Tanaporn Toothong; Mathuros Tipayamongkholgul; Nawarat Suwannapong; Saravudh Suvannadabba
Journal:  BMC Public Health       Date:  2015-09-28       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.